U.S. FDA Grants Accelerated Approval For Iovance’s Skin Cancer Therapy

Feb 16 (Reuters) – Iovance Biotherapeutics (IOVA.O), opens new tab said on Friday the U.S. health regulator has granted an accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approved for the deadliest form of skin cancer.